Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Company News

Neurocrine gets rights to Bial-Portela's PD drug

Chris Lieu
February 10, 2017 10:24 PM UTC

Bial-Portela & Ca. S.A. (S. Mamede do Coronado, Portugal) granted Neurocrine Biosciences Inc. (NASDAQ:NBIX) exclusive, North American rights to Parkinson's disease drug Ongentys opicapone (ONO-2370).

Bial-Portela will receive $30 million up front and is eligible for $115 million in milestones, plus 37% of net sales in exchange for manufacturing and supplying the drug...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Bial-portela & Ca. S.A.

Neurocrine Biosciences Inc.